resTORbio

General Information
Business:

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Our lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies. The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly.

 

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 7
Founded: 2016
Contact Information
Address 501 Boylston Street, Suite 6102, Boston, MA 02116, US
Phone Number (617) 482-2333
Web Address http://www.restorbio.com
View Prospectus: resTORbio
Financial Information
Market Cap $407.9mil
Revenues $0 mil (last 12 months)
Net Income $-10.7 mil (last 12 months)
IPO Profile
Symbol TORC
Exchange NASDAQ
Shares (millions): 5.7
Price range $15.00 - $15.00
Est. $ Volume $85.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Leerink Partners/ Evercore ISI
CO-Managers Wedbush PacGrow
Expected To Trade: 1/26/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change